To The Moon

$HOOD CUSTOM 260123/260123/260116 PUT 96.0/PUT 108.0/PUT 110.0$ Rolling from last week with lower strike, and I also buy put to lower margin requirement 

$GLXY 20260116 35.0 CALL$ Huge trading volume and expanding assets under management, highlighting institutional crypto demand. Its Helios AI/data-center buildout has doubled approved power capacity, tapping booming AI infrastructure markets. A recent $460M strategic investment strengthens its balance sheet for expansion.  

$STI ETF(ES3.SI)$ Stacking dividends and consolidating portfolio! We in for a rough 2026!

$American Express(AXP)$ AXP Climbs +2.08%: Bouncing from Support, Eyes $370 Amid Strong Institutional FlowLatest Close Data: AXP closed at $364.79 on 2026-01-18, up +2.08% (+$7.42). The stock is now about 5.86% below its 52-week high of $387.49.Core Market Drivers: The positive move appears driven by strong net capital inflows ($30M net positive on the day), suggesting institutional accumulation. The broader financial sector remains sensitive to interest rate expectations and consumer spending trends.Technical Analysis: Volume was slightly below average (Volume Ratio: 0.89), indicating the rally lacked explosive retail participation. However, the RSI(6) jumped from 25.0 to 44.8, signaling a strong rebound from oversold conditions. MACD remains nega

$IBM(IBM)$ IBM Rallies +2.59%: Blue-Chip Giant Eyes $310 BreakoutLatest Close Data: On 2026-01-18, IBM closed at $305.67, up +2.59% (+$7.72). This places it $19.23 (5.9%) below its 52-week high of $324.90.Core Market Drivers: Positive sentiment likely fueled by renewed focus on enterprise AI and hybrid cloud solutions, core pillars of IBM's strategy. A stable dividend yield of 2.19% continues to attract income-focused investors in a volatile market.Technical Analysis: The rally was supported by strong volume (Volume Ratio: 1.60). The MACD (DIF: 0.3416, DEA: -0.0319, MACD: 0.7470) has crossed above its signal line, generating a fresh bullish signal. The RSI(12) at 52.32 is in neutral territory, suggesting room for further upside without immediate ov

$Quanta(PWR)$ PWR Rallies +4.27%: Power Infrastructure Leader Hits 52-Week High, $480 Target in SightLatest Close DataClosed at $466.75 (USD) on 2026-01-18, surging +4.27% with a daily gain of $19.11. The stock is now trading at its 52-week high of $480.93.Core Market DriversThe rally is fueled by strong institutional capital inflow over the past five days and positive sentiment in the infrastructure sector. The stock successfully tested and held above its previous resistance level.Technical AnalysisVolume surged to 2.22 million shares with a Volume Ratio of 2.56, confirming strong buying interest. The MACD (12,26,9) shows a powerful bullish crossover with DIF at 1.80 turning positive above DEA at -1.76, generating a strong buy signal (MACD bar: 7.

$Quince Therapeutics, Inc.(QNCX)$ QNCX Soared +23.26%: Biotech Surge Breaks Resistance, $3.6 Pivot HoldsLatest Close DataClosed at $3.55 on Jan 18, 2026, surging +23.26% from the previous close. The stock is now just -22% below its 52-week high of $4.55.Core Market DriversThe strong move was driven by a significant net capital inflow of $554k and high retail participation. The volume ratio of 1.98 indicates robust buying interest, likely fueled by positive sentiment in the biotech sector and the company's ongoing preclinical developments.Technical AnalysisThe surge was accompanied by heavy volume (2.86M shares). The 6-day RSI spiked to 72.16, entering overbought territory, signaling strong short-term momentum. MACD shows a bullish signal with the

$TNL Mediagene(TNMG)$ TNMG Soared +65.68%: Media Stock Erupts on Extreme Volume, $3.91 Close Signals ReversalLatest Close DataClosed at $3.91 on 2026-01-19, surging +65.68% from yesterday's $2.36 close. The price remains far below its 52-week high of $120.00.Core Market DriversThe massive spike was primarily driven by extreme retail trading activity, with a daily turnover rate of 1344.02% and volume ratio over 400. No specific company news was cited, suggesting a potential short squeeze or speculative momentum play.Technical AnalysisVolume exploded to 27.76M shares, far above average. The 6-day RSI jumped to 78.42, entering overbought territory, while the 12-day RSI at 60.80 shows strong momentum. MACD histogram turned positive to 0.347, signaling

$ImmunityBio, Inc.(IBRX)$ IBRX Explodes +39.75%: Biotech Rocket Hits 52-Week High, Momentum PeaksLatest Close Data: IBRX closed at $5.52 on Jan 18, surging +39.75% with a massive 30.38% intraday range. It touched its 52-week high of $5.58 during the session.Core Market Drivers: The biotech sector saw broad positive sentiment. Specific catalysts for IBRX's explosive move were not detailed in the provided news data, but such moves are often driven by clinical trial updates, FDA-related news, or significant institutional positioning.Technical Analysis: The surge was backed by enormous volume (182M shares, Volume Ratio 4.96), confirming strong buying interest. The RSI(6) at 98.8 and RSI(12) at 94.2 are deeply in overbought territory, signaling extreme

$Affirm Holdings, Inc.(AFRM)$ AFRM Rallies +4.11%: Buy Now, Pay Later Leader Tests $76 ResistanceLatest Close DataAFRM closed at $74.76 on 2026-01-19, gaining +4.11%. The stock is now ~25% below its 52-week high of $100.00.Core Market DriversThe rally is supported by sustained strong consumer spending data and the stock's recent oversold condition. Affirm's leadership in the "Buy Now, Pay Later" space continues to attract investor interest, despite ongoing market scrutiny of fintech valuations.Technical AnalysisToday's volume of 5.62M shares was below average (Volume Ratio: 0.84), suggesting a lack of strong conviction. The MACD histogram remains negative at -1.67, indicating bearish momentum persists. The 6-day RSI rebounded sharply to 43.85 from

$CytomX Therapeutics(CTMX)$ CTMX Exploded +26.82%: Biotech Surge Hits 52-Week High, Volume Spikes 5.88xLatest Close Data: Closed at $5.39 on 2026-01-18, a massive +26.82% surge. This price equals the 52-week high of $5.70, indicating a critical breakout test.Core Market Drivers: The stock's dramatic rise appears driven by strong positive sentiment in the biotech sector and potential anticipation of upcoming clinical catalysts specific to CytomX's pipeline. High retail participation (small order net buying) contributed to the day's volatility.Technical Analysis: Explosive volume of 13.4M shares (Volume Ratio 5.88) confirms the breakout strength. RSI(6) at 84.05 signals overbought conditions, suggesting a near-term pullback is possible. MACD shows a